Sirolimus conversion after liver transplantation: Improvement in measured glomerular filtration rate after 2 years

Transplantation Proceedings

Volumn 37, Issue 10, 2005, Pages 4416-4423

  Sanchez, E Q ^a   Martin, A P ^a   Ikegami, T ^a   Uemura, T ^a   Narasimhan, G ^a   Goldstein, R M ^a   Levy, M F ^a   Chinnakotla, S ^a   Dawson III, S ^a   Randall, H B ^a   Saracino, G ^a   Klintmaim, G B ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; IOTALAMIC ACID I 125; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS;

ANEMIA; BACTERIAL INFECTION; COMA; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DEEP VEIN THROMBOSIS; DRUG BLOOD LEVEL; DRUG SAFETY; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; HEMODIALYSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; LEUKOPENIA; LIVER TRANSPLANTATION; MYCOSIS; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; TIME SERIES ANALYSIS; WOUND INFECTION;

EID: 29544443572     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2005.10.019     Document Type: Article

References (28)

1. B.D. Kahan Cyclosporin A, FK506, rapamycin the use of a quantitative analytic tool to discriminate immunosuppressive drug interactions J Am Soc Nephrol 2 suppl 1992 S222
2. R.Y. Calne, D.S. Collier, S. Lim Rapamycin for immunosuppression in organ allografting Lancet 2 1989 227
3. D.S. Collier, R. Calne, S. Thiru Rapamycin in experimental renal allografts in dogs and pigs Transplant Proc 22 1990 1674
4. D.S. Collier, R.Y. Calne, S.G. Pollard Rapamycin in experimental renal allografts in primates Transplant Proc 23 1991 2246
5. J.M. Guilbeau Delayed wound healing with sirolimus after liver transplant Ann Pharmacother 36 2002 1391
6. E. Morelon, M. Stern, D. Israel-Biet, J.M. Correas Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients Transplantation 72 2001 787
7. J.F. Trotter, M.E. Wachs, T.E. Trouillot Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus Liver Transplant 7 2001 401
8. C.G. Groth, L. Backman, J.M. Morales Sirolimus European Renal Transplant Study Group Sirolimus (rapamycin)-based therapy in human renal transplantation similar efficacy and different toxicity compared with cyclosporine Transplantation 67 1999 1036
9. F. Vincenti, E. Ramos, C. Brattstrom Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation Transplantation 71 2001 1282
10. R.W. Johnson, H. Kreis, R. Oberbauer Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure Transplantation 72 2001 777
11. T.A. Gonwa, D.E. Hricik, K. Brinker Sirolimus Renal Function Study Group Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination Transplantation 74 2002 1560
12. J. Neuberger Renal failure late after liver transplantation Liver Transplan 8 2002 922
13. A.J. Cohen, M.D. Stegall, C.B. Rosen Chronic renal dysfunction late after liver transplantation Liver Transplant 8 2002 916
14. T.A. Gonwa, G.B. Klintmalm, M. Levy Impact of pretransplant renal function on survival after liver transplantation Transplantation 59 1995 361
15. T.A. Gonwa, M.L. Mai, L.B. Melton Renal replacement therapy and orthotopic liver transplantation the role of continuous veno-venous hemodialysis Transplantation 71 2001 1424
16. T.A. Gonwa, M.L. Mai, L.B. Melton End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy risk of development and treatment Transplantation 72 2001 1934
17. J.F. Trotter, M. Wachs, T. Bak Liver transplantation using sirolimus and minimal corticosteroids (3-day taper) Liver Transplant 7 2001 343
18. G.J. Chang, H.D. Mahanty, D. Quan Experience with the use of sirolimus in liver transplantation use in patients for whom calcineurin inhibitors are contraindicated Liver Transplant 6 2000 734
19. C.J. Watson, P.J. Friend, N.V. Jamieson Sirolimus a potent new immunosuppressant for liver transplantation Transplantation 67 1999 505
20. J. Zhu, J. Wu, E. Frizell Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis Gastroenterology 117 1999 1198
21. A. Jain, J. Reyes, R. Kashyap Long-term survival after liver transplantation in 4,000 consecutive patients at a single center Ann Surg 232 2000 490
22. N.C. Fisher, P.G. Nightingale, B.K. Gunson Chronic renal failure following liver transplantation a retrospective analysis Transplantation 66 1998 59
23. M. Lynn, K. Abreo, G. Zibari End-stage renal disease in liver transplants Clin Transplant 15 suppl 6 2001 66
24. M.K. Porayko, T.A. Gonwa, G.B. Klintmalm US Multicenter Liver Study Group Comparing nephrotoxicity of FK 506 and cyclosporine regimens after liver transplantation preliminary results from US multicenter trial Transplant Proc 27 1995 1114
25. V.R. Dharnidharka, C. Kwon, G. Stevens Serum cystatin C is superior to serum creatinine as a marker of kidney function a meta-analysis Am J Kidney Dis 40 2002 221
26. A. Shimizu-Tokiwa, M. Kobata, H. Io Serum cystatin C is a more sensitive marker of glomerular function than serum creatinine Nephron 92 2002 224
27. O. Schuck, H. Gottfriedova, J. Maly Glomerular filtration rate assessment in individuals after orthotopic liver transplantation based on serum cystatin C levels Liver Transplant 8 2002 594
28. G.D. Tan, A.V. Lewis, T.J. James Clinical usefulness of cystatin C for the estimation of glomerular filtration rate in type 1 diabetes reproducibility and accuracy compared with standard measures and iohexol clearance Diabetes Care 25 2002 2004